Stock Market & Financial Investment News

News Breaks December 14, 2012 05:05 EDT VNDA Vanda Pharmaceuticals receives negative opinion from CHMP on Fanaptum Vanda Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Product for Human Use, or CHMP, has issued a negative opinion recommending against approval of Fanaptum for the treatment of schizophrenia in adult patients in the European Union. The CHMP was of the opinion that the benefits of Fanaptum did not outweigh its risks and recommended against marketing authorization at this point in time. Vanda intends to appeal this opinion and request a re-examination of the decision by the CHMP. News For VNDA From The Last 14 Days Check below for free stories on VNDA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 09:59 EDT VNDA Vanda Pharmaceuticals management to meet with Lazard Capital Subscribe for More Information May 17, 2013 11:39 EDT VNDA High option volume stocks: GNK VNDA BYI ARUN BYI ILMN Subscribe for More Information 07:37 EDT VNDA Vanda Pharmaceuticals price target raised to $17 from $11 at Lazard Capital Subscribe for More Information May 9, 2013 06:59 EDT VNDA Vanda Pharmaceuticals sees FY13 operating expense $57M-$62M Subscribe for More Information 06:57 EDT VNDA Vanda Pharmaceuticals reports Q1 EPS (15c), consensus (25c) Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.